A Case of Aggravation of Thyroid Goiter after Treatment with PD-1 Inhibitor for Breast Cancer in Patients with Underlying Hashimoto's Thyroiditis
10.11106/ijt.2018.11.2.172
- Author:
Hana KIM
1
;
Min Joo KIM
;
Young Shin SONG
;
Sun Wook CHO
Author Information
1. Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. swchomd@gmail.com
- Publication Type:Case Report
- Keywords:
PD-1 inhibitor;
Immune-related adverse events (irAEs);
Hashimoto's thyroiditis;
Goiter
- MeSH:
Adult;
Breast Neoplasms;
Breast;
Drug Therapy;
Female;
Goiter;
Humans;
Hyperventilation;
Immune System;
Immune Tolerance;
Ligands;
Programmed Cell Death 1 Receptor;
T-Lymphocytes;
Thyroid Gland;
Thyroiditis
- From:International Journal of Thyroidology
2018;11(2):172-175
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Anti-programmed cell death-1 (PD-1) humanized monoclonal antibody inhibits PD-1 activity by binding to the PD-1 receptor on T-cells and blocking PD-1 ligands and induces immune tolerance of cancer cells. It has been widely used for various kinds of cancer treatment. However, many immune-related adverse events (irAEs) have been reported because it modulates our immune system. In this case study, we reported a case of 42-year-old woman with Hashimoto's thyroiditis who showed rapid aggravation of thyroid goiter and acute hyperventilation syndrome after treatment with PD-1 inhibitor as a neoadjuvant chemotherapy for breast cancer.
